A Phase I/II Dose Escalation and Proof-of-Concept Study of MK2461 in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I/II
Latest Information Update: 02 Apr 2015
At a glance
- Drugs MK 2461 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 12 Mar 2012 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 24 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.